查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1983948

抗菌素抗藥性監測市場：按交付方式、技術、應用和最終用戶分類－2026-2032年全球預測

Antimicrobial Resistance Surveillance Market by Offering, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年抗菌藥物抗藥性監測市場價值為 63 億美元，預計到 2026 年將成長至 66.7 億美元，複合年成長率為 6.83%，到 2032 年將達到 100.1 億美元。

主要市場統計數據
基準年 2025 63億美元
預計年份：2026年 66.7億美元
預測年份 2032 100.1億美元
複合年成長率 (%) 6.83%

引人入勝的引言將抗菌素抗藥性監測定位為一項緊迫的臨床、技術和系統性挑戰，需要綜合診斷和數據。

抗菌藥物抗藥性監測處於臨床緊迫性、技術進步和公共衛生策略的交匯點，需要持續有效地實施，並清晰地呈現挑戰和不斷變化的應對情況。引言部分概述了協作監測對於維持治療效果至關重要的原因。細菌病原體抗藥性的日益增強正在重塑診斷重點，加速了對快速表現型和基因分型檢測的需求，並迫使檢查室和醫療保健系統重新思考如何在網路間收集、分析和共用數據。除了臨床影響之外，監測系統在食品安全、環境監測和流行病學資訊方面也日益發揮核心作用，這擴大了相關人員的範圍，並增加了對可互通資料標準和安全資訊交流的需求。

對重塑全球抗菌素抗藥性監測系統的關鍵技術、營運和政策主導變革進行了深入分析。

抗菌藥物抗藥性監測領域正經歷一場變革，其驅動力包括技術成熟、政策推動以及相關人員不斷變化的期望。本節將詳細闡述這項變革的關鍵促進因素。快速表現型檢測和高通量定序的進步縮短了從檢體採集到獲得可操作資訊的時間，從而能夠更精準地使用抗菌藥物並及早發現新的抗藥性模式。同時，數位健康平台和檢查室資訊系統正在促進臨床、公共衛生、食品安全和環境等領域之間更豐富的數據整合，從而強化了從孤立的檢測事件向持續監測的轉變。這些技術變革，加上監管力度的加強和對資料透明度日益成長的期望，正迫使各組織加強檢驗流程並投資於互通性標準。

對近期關稅變化如何影響整個監控生態系統的採購趨勢、供應彈性策略和營運計劃進行全面評估。

2025年實施的關稅措施的累積影響，為診斷試劑、其他試劑和實驗室設備的採購計算引入了新的變數。本節將追蹤這些措施的實際影響，而不依賴數值預測。進口關稅的提高及相關貿易政策措施，加劇了依賴跨境供應鏈獲取關鍵耗材和複雜設備的檢查室和醫療系統的成本壓力。為此，採購團隊和供應商組織正日益重視貨源多元化、本地生產夥伴關係以及庫存最佳化策略，以減少對單一國家的依賴。同時，這些貿易變化也使得基於服務的交付模式和試劑租賃項目更具吸引力，因為它們可以作為緩衝機制，幫助醫療機構抵禦資本支出波動帶來的風險。

詳細的細分洞察揭示了產品陣容、技術、應用和最終用戶需求如何結合起來，決定監控優先順序和採購行為。

關鍵的市場細分洞察揭示了產品、技術、應用和最終用戶等維度如何相互交織，從而影響抗菌藥物抗藥性監測的採購重點、營運流程和投資選擇。按產品分類，市場涵蓋耗材和試劑、儀器、服務和軟體。在耗材和試劑中，抗生素檢測板、培養基和PCR試劑盒尤為突出，它們在監測過程中各自發揮特定作用，並具有各自的供應和檢驗要求。儀器涵蓋了從手動抗菌藥物敏感性試驗（AST）台到全自動系統和質譜儀等多種平台。同時，服務和軟體支援遠端數據分析、品質保證以及將監測結果整合到臨床決策支援系統中。

這項針對特定區域的分析揭示了特定區域的基礎設施、採購框架和製造能力如何影響監測實施和供應商策略。

區域趨勢對監測重點、供應鏈和診斷技術的應用曲線有顯著影響。本節概述了關鍵區域的獨特背景和戰略意義。在美洲，完善的公共衛生基礎設施和集中的參考檢查室支援早期採用定序和自動化抗菌藥物敏感性檢測技術，而採購週期和報銷機制則影響供應商的合作模式。此外，北美和南美之間的區域互聯互通促進了集體爆發監測和數據共用的合作網路，這反過來又影響著供應商如何定位其整合硬體和軟體解決方案以及服務產品。

切實可行的企業級洞察突顯了整合平台、供應鏈韌性和夥伴關係模式如何重新定義監控解決方案的競爭優勢。

抗菌素抗藥性監測領域的企業正從單一產品策略轉向整合硬體、試劑、資訊學和服務的一體化解決方案。本節概述了決定競爭地位的策略性舉措。領先的診斷和生命科學供應商正在投資模組化平台，以支援表現型和基因型檢測途徑，從而幫助客戶簡化工作流程並降低複雜性。同時，試劑專家正在開發檢驗的檢測組合，以簡化監管合規流程並加速在各種實驗室環境中的部署。隨著互通性和數據分析成為尋求端到端監測能力的客戶的關鍵差異化因素，儀器製造商和軟體開發商之間的策略夥伴關係也日益普遍。

為高階主管和職能領導提供實際有效的建議，以增強營運中監測的韌性、互通性和臨床效用。

行業領導者必須採取有針對性、可操作的策略，將監測數據轉化為營運韌性和臨床影響。本節概述了一系列針對高階主管和職能領導者的高效建議。首先，應優先考慮供應商多元化和合約機制，以確保關鍵耗材和備件的供應，而不是將組織束縛於單一供應商。與區域供應商建立關係並採用靈活的採購模式可以顯著降低營運風險。其次，應投資可互通的資料架構和檢驗的分析方法，將檢查室結果與臨床和公共衛生系統連接起來。互通性能夠實現更快的偵測、集中監控以及跨組織邊界的協作回應。第三，應加快有針對性的自動化和數位化工作流程，將熟練人員從重複性工作中解放出來，同時提高可重複性和處理能力。將自動化與能力發展計畫結合，可以保持人才儲備。

我們透明且可重複的調查方法，結合了相關人員訪談、文獻整合、專家檢驗和跨區域比較，為我們得出可靠的結論提供了支持。

本分析的調查方法結合了定性和定量方法，旨在得出穩健的、基於證據的結論，同時保持資料來源和檢驗過程的透明度。主要研究包括對檢查室管理人員、採購負責人、臨床微生物學家、公共衛生官員和技術供應商進行結構化訪談，以收集關於營運挑戰、採購行為和技術應用障礙的第一手觀點。此外，還對同行評審文獻、監管指南、技術白皮書和已發表的臨床檢驗研究進行了全面審查，這些研究詳細闡述了檢測方法的性能特徵和工作流程整合方面的考慮因素。

總結整合工作，強調對技術、互通性和供應彈性進行協調投資，以保護治療效果和公共衛生結果。

總之，抗菌素抗藥性監測正從一系列獨立的檢查室活動轉向一個協調一致、數據驅動的系統，涵蓋臨床護理、公共衛生、食品安全和環境監測。快速表現型檢測、定序和數位分析技術的進步使得監測訊號更加豐富，介入措施也更加迅速，但要充分發揮這些潛力，需要對互通性、人力資源能力和供應鏈韌性進行有意識的投資。政策變化、採購壓力和不斷演進的經營模式相互交織，要求各組織在短期營運連續性和長期能力建設之間取得平衡。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 抗菌素抗藥性監測市場：依產品/服務分類

  • 耗材和試劑
    • 抗生素檢測
    • 培養基
    • PCR試劑盒
  • 裝置
  • 服務
  • 軟體

第9章 抗菌素抗藥性監測市場：依技術分類

  • 自動化AST系統
  • 手動AST
  • 質譜分析
  • 次世代定序
  • 即時PCR

第10章：抗菌素抗藥性監測市場：依應用領域分類

  • 環境監測
  • 流行病學監測
  • 食品安全檢查
  • 感染控制

第11章 抗菌素抗藥性監測市場：依最終用戶分類

  • 學術研究機構
  • 臨床檢查室
  • 醫院檢查室
  • 製藥和生物技術公司
  • 標準檢驗組織

第12章 抗菌素抗藥性監測市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 抗菌藥物抗藥性監測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 抗菌素抗藥性監測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國抗菌素抗藥性監測市場

第16章：中國抗菌素抗藥性監測市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accelerate Diagnostics, Inc.
  • Alifax Srl
  • Becton, Dickinson and Company
  • bioMerieux SA
  • BioSpace, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Liofilchem Srl
  • Lumed, Inc.
  • Luminex Corporation
  • Merck & Co., Inc.
  • Oxford Nanopore Technologies plc
  • Pfizer Inc.
  • QIAGEN NV
  • Seegene, Inc.
  • Siemens Healthineers AG
  • SyntBioLab, Inc.
  • T2 Biosystems, Inc.
  • Thermo Fisher Scientific, Inc.
  • Wolters Kluwer NV
Product Code: MRR-CF6C60CF95A8

The Antimicrobial Resistance Surveillance Market was valued at USD 6.30 billion in 2025 and is projected to grow to USD 6.67 billion in 2026, with a CAGR of 6.83%, reaching USD 10.01 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.30 billion
Estimated Year [2026] USD 6.67 billion
Forecast Year [2032] USD 10.01 billion
CAGR (%) 6.83%

A compelling introduction that frames antimicrobial resistance surveillance as an urgent clinical, technological, and systems-level priority requiring integrated diagnostics and data

Antimicrobial resistance surveillance sits at the intersection of clinical urgency, technological advancement, and public health strategy, requiring a coherent introduction that frames the challenge and the evolving response landscape. The opening assessment synthesizes why coordinated surveillance is foundational to preserving therapeutic efficacy: rising resistance profiles among bacterial pathogens are reshaping diagnostic priorities, accelerating demand for rapid phenotypic and genotypic testing, and forcing laboratories and health systems to reconsider how data is collected, analyzed, and shared across networks. In addition to clinical implications, surveillance systems are increasingly central to food safety, environmental monitoring, and epidemiological intelligence, thereby broadening the stakeholder base and amplifying requirements for interoperable data standards and secure information exchange.

Moreover, the contemporary introduction emphasizes the convergence of instrumentation, consumables, informatics, and services as integral components of an effective surveillance ecosystem. Diagnostic manufacturers, reagent suppliers, software developers, and service providers must coordinate to deliver integrated solutions that support real-time decision making. This introduction also acknowledges the operational pressures felt by laboratories, including workforce constraints, supply chain volatility, and regulatory requirements, while underscoring how investments in automation, sequencing, and analytics can enhance throughput and generate higher-fidelity surveillance signals. Ultimately, the introduction sets the stage for a report that balances technical detail with strategic implications, positioning surveillance as both a clinical necessity and a systems-level capability that demands sustained investment and cross-sector collaboration

Insightful analysis of the major technological, operational, and policy-driven shifts reshaping antimicrobial resistance surveillance systems worldwide

The landscape for antimicrobial resistance surveillance is undergoing transformative shifts driven by technological maturation, policy momentum, and changing stakeholder expectations, and this section details the principal vectors of change. Advances in rapid phenotypic testing and high-throughput sequencing have shortened the time from sample to actionable insight, enabling more precise antimicrobial stewardship and earlier detection of emerging resistance patterns. Concurrently, digital health platforms and laboratory information systems are enabling richer data linkages across clinical, public health, food safety, and environmental domains, reinforcing the shift from isolated testing events to continuous surveillance streams. These technological changes are complemented by growing regulatory scrutiny and heightened expectations for data transparency, prompting organizations to strengthen validation pathways and invest in interoperability standards.

In parallel, an operational recalibration is occurring across supply chains and service models. Laboratories are balancing in-house capability expansion with outsourced testing partnerships, while manufacturers are rethinking production flexibility and distribution strategies to mitigate supply disruptions. Workforce dynamics are also shifting: skilled laboratory professionals face increased demand, and organizations are deploying automation and remote-support models to preserve capacity. Taken together, these trends are not simply incremental; they are altering how surveillance programs are designed, funded, and operated. Decision-makers must therefore adapt governance models, invest in resilient supply relationships, and prioritize technologies that integrate seamlessly into existing clinical and public health workflows

Comprehensive evaluation of how recent tariff shifts are altering procurement dynamics, supply resilience strategies, and operational planning across surveillance ecosystems

The cumulative effect of tariff measures enacted in 2025 has introduced new variables into the procurement calculus for diagnostics, reagents, and laboratory instrumentation, and this section traces the practical implications without presuming numerical projections. Higher import duties and related trade policy measures have intensified the cost pressures on laboratories and health systems that rely on cross-border supply chains for critical consumables and complex instruments. In response, procurement teams and supplier organizations have increasingly prioritized diversification of sourcing, localized manufacturing partnerships, and inventory optimization strategies aimed at reducing single-country dependency. At the same time, these trade shifts have reinforced the attractiveness of service-based delivery models and reagent rental programs that can buffer facilities from capital expenditure volatility.

Regulatory and compliance burdens have also been affected, as increased tariffs may trigger adjustments in supplier contracts, customs processes, and lead-time expectations, necessitating more rigorous supplier performance monitoring and contractual protections. For manufacturers, the tariff environment has accelerated strategic decisions around regional manufacturing footprints and tariff engineering to preserve competitiveness. Health systems and reference labs are consequently adapting by strengthening demand forecasting, expanding collaborative purchasing consortia, and exploring homologation strategies to qualify alternative suppliers more rapidly. Importantly, these responses underscore a broader trend toward supply chain resilience and operational flexibility, where procurement agility and supplier transparency become as critical as product performance in sustaining effective antimicrobial resistance surveillance

In-depth segmentation insights revealing how product offerings, technologies, applications, and end-user needs collectively determine surveillance priorities and procurement behaviors

Key segmentation insights illuminate how distinct product, technology, application, and end-user dimensions intersect to shape procurement priorities, operational workflows, and investment choices within antimicrobial resistance surveillance. When examining the market by offering, the landscape spans consumables and reagents, instruments, services, and software; within consumables and reagents, attention centers on antibiotic panels, culture media, and PCR kits, each of which plays a specific role in surveillance pathways and has discrete supply and validation requirements. Instruments encompass a range of platforms from manual AST benches to fully automated systems and mass spec analyzers, while services and software enable remote data interpretation, quality assurance, and the integration of surveillance outputs into clinical decision support systems.

From a technology perspective, automated antimicrobial susceptibility testing systems, manual AST methods, mass spectrometry platforms, next-generation sequencing workflows, and real-time PCR assays present distinct trade-offs in turnaround time, sensitivity, and operational complexity. Applications drive adoption priorities differently: environmental monitoring emphasizes robust sample handling and throughput, epidemiological surveillance prioritizes data continuity and lineage tracing, food safety testing requires stringent traceability, and infection control focuses on rapid detection at the point of care or within hospital laboratories. End users further shape procurement and deployment models: academic and research institutes value configurability and depth of data, clinical laboratories and hospital laboratories prioritize throughput and regulatory compliance, pharmaceutical and biotechnology companies require stringent controls for development programs, and reference laboratories demand scalable, high-volume platforms. Understanding these segmentation dynamics is essential for aligning product development, commercialization strategies, and service models with the real-world needs of diverse stakeholders

Targeted regional analysis that clarifies how geographically specific infrastructure, purchasing frameworks, and manufacturing capabilities shape surveillance implementation and supplier strategies

Regional dynamics exert strong influence on surveillance priorities, supply chains, and the adoption curve for diagnostic technologies; this section synthesizes the distinct conditions and strategic implications across major geographies. In the Americas, established public health infrastructures and a concentration of reference laboratories support advanced adoption of sequencing and automated susceptibility testing, while procurement cycles and reimbursement frameworks shape supplier engagement models. Furthermore, regional interconnectivity in North and South America has prompted collaborative networks for outbreak detection and data sharing, which in turn influence how vendors position integrated hardware-software solutions and service offerings.

Across Europe, the Middle East and Africa, heterogeneity defines both challenge and opportunity. Well-resourced systems in parts of Western Europe have accelerated adoption of data-driven surveillance platforms and value digital interoperability, whereas resource-constrained settings in other parts of the region prioritize affordability, robustness, and ease of use. As a result, suppliers tailor portfolios to meet a wide spectrum of needs, often combining low-complexity, high-reliability assays with scalable software tools. In the Asia-Pacific region, diverse manufacturing capabilities, rapid technology diffusion, and significant investments in public health genomics create a dynamic marketplace for sequencing, real-time PCR, and automated AST solutions. Regional supply chain capabilities and domestic production policies also influence procurement choices, making local partnership strategies and flexible commercial models particularly effective for achieving deployment at scale

Actionable company-level insights highlighting how integrated platforms, supply resilience, and partnership models are redefining competitive advantage in surveillance solutions

Companies operating in the antimicrobial resistance surveillance space are evolving beyond single-product strategies toward integrated solution sets that combine hardware, reagents, informatics, and services, and this section distills the strategic moves that define competitive positioning. Leading diagnostic and life-science suppliers are investing in modular platforms that support both phenotypic and genotypic testing pathways, enabling clients to consolidate workflows and reduce complexity. At the same time, reagent specialists are developing validated assay panels that simplify regulatory compliance and accelerate deployment across heterogeneous laboratory environments. Strategic partnerships between instrument manufacturers and software developers are increasingly common, as interoperability and data analytics become critical differentiators for customers seeking end-to-end surveillance capabilities.

Additionally, many organizations are strengthening supply chain transparency and resilience through regional manufacturing, multi-sourcing strategies, and service contracts that bundle consumables with training and remote support. Sales and commercialization teams are adapting by offering flexible procurement models, including subscription and reagent-rental arrangements, which can lower adoption barriers for resource-constrained facilities. R&D priorities among companies reflect an emphasis on faster time-to-result, improved analytical sensitivity, and streamlined sample-to-answer workflows, while commercial strategies emphasize integrated clinical validation and health-economics evidence to support adoption. Together, these company-level trends signal a maturing market where technological breadth, supply reliability, and data integration increasingly determine competitive advantage

Practical, high-impact recommendations for executives and functional leaders to strengthen surveillance resilience, interoperability, and clinical utility across operations

Industry leaders must adopt focused, pragmatic strategies to translate surveillance intelligence into operational resilience and clinical impact, and this section outlines a set of high-impact recommendations tailored to senior executives and functional leaders. First, prioritize supplier diversification and contractual mechanisms that secure critical consumables and spare parts without locking organizations into single-source dependencies; building regional supplier relationships and embracing flexible procurement models can materially reduce operational risk. Second, invest in interoperable data architectures and validated analytics that connect laboratory outputs with clinical and public health systems; interoperability enables faster detection, centralized monitoring, and coordinated responses across institutional boundaries. Third, accelerate targeted automation and digital workflows that relieve skilled personnel from repetitive tasks while improving reproducibility and throughput; combine automation with competency development programs to maintain workforce depth.

Fourth, realign product and service portfolios around modular integration, ensuring that instruments, reagents, and software can be deployed in layered configurations that meet diverse end-user needs. Fifth, embed regulatory and quality assurance planning into product roadmaps to streamline approvals and enhance trust among clinical customers. Finally, foster collaborative models with public health agencies, academic centers, and industry partners to co-develop sentinel surveillance projects and pilot implementations; these collaborations generate operational evidence, validate real-world performance, and create pathways for scaled adoption. Implementing these recommendations requires disciplined governance, prioritized investment, and a focus on measurable outcomes tied to clinical utility and system resilience

Transparent and reproducible research methodology combining stakeholder interviews, literature synthesis, expert validation, and cross-regional comparison to support robust conclusions

The research methodology underpinning this analysis blends qualitative and quantitative approaches to ensure robust, evidence-based conclusions while maintaining transparency about data sources and validation processes. Primary research included structured interviews with laboratory leaders, procurement specialists, clinical microbiologists, public health officials, and technology vendors to capture first-hand perspectives on operational challenges, procurement behaviors, and technology adoption barriers. These insights were supplemented by a comprehensive review of peer-reviewed literature, regulatory guidance, technical whitepapers, and published clinical validation studies that detail assay performance characteristics and workflow integration considerations.

To ensure analytical rigor, findings were triangulated across multiple sources and subjected to expert validation rounds, where independent subject-matter experts reviewed assumptions, interpreted technical trade-offs, and assessed the operational feasibility of recommended actions. The methodology also incorporated cross-regional comparisons to highlight contextual differences and to identify where localized strategies are necessary. Limitations include variability in reporting standards across institutions and the evolving nature of regulatory pathways for new diagnostic modalities, which were addressed through conservative interpretation of qualitative data and transparent documentation of data provenance. Overall, the methodological approach emphasizes reproducibility, stakeholder validation, and the translation of technical evidence into actionable strategic guidance

Conclusive synthesis emphasizing coordinated investment in technology, interoperability, and supply resilience to protect therapeutic efficacy and public health outcomes

In conclusion, antimicrobial resistance surveillance is transitioning from a collection of discrete laboratory activities into a coordinated, data-driven system that spans clinical care, public health, food safety, and environmental monitoring. Technological advances in rapid phenotypic testing, sequencing, and digital analytics are enabling richer surveillance signals and faster interventions, but realizing this potential requires intentional investment in interoperability, workforce capacity, and supply chain resilience. The confluence of policy changes, procurement pressures, and evolving commercial models means that organizations must balance near-term operational continuity with longer-term capability building.

The synthesis underscores the importance of modular solutions that can be adapted to diverse laboratory settings, the necessity of diversified supplier strategies in the face of trade and tariff disruption, and the strategic value of integrated software and service offerings that translate raw data into actionable insights. Leaders who proactively align procurement, technology adoption, and governance will be better positioned to detect emerging resistance trends, support antimicrobial stewardship programs, and protect patient outcomes. This conclusion is a call to action for coordinated effort across manufacturers, laboratories, policymakers, and funders to prioritize surveillance as a foundational public health asset

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antimicrobial Resistance Surveillance Market, by Offering

  • 8.1. Consumables And Reagents
    • 8.1.1. Antibiotic Panels
    • 8.1.2. Culture Media
    • 8.1.3. PCR Kits
  • 8.2. Instruments
  • 8.3. Services
  • 8.4. Software

9. Antimicrobial Resistance Surveillance Market, by Technology

  • 9.1. Automated AST Systems
  • 9.2. Manual AST
  • 9.3. Mass Spectrometry
  • 9.4. Next Generation Sequencing
  • 9.5. Real Time PCR

10. Antimicrobial Resistance Surveillance Market, by Application

  • 10.1. Environmental Monitoring
  • 10.2. Epidemiological Surveillance
  • 10.3. Food Safety Testing
  • 10.4. Infection Control

11. Antimicrobial Resistance Surveillance Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Clinical Laboratories
  • 11.3. Hospital Laboratories
  • 11.4. Pharmaceutical And Biotechnology Companies
  • 11.5. Reference Laboratories

12. Antimicrobial Resistance Surveillance Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Antimicrobial Resistance Surveillance Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Antimicrobial Resistance Surveillance Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Antimicrobial Resistance Surveillance Market

16. China Antimicrobial Resistance Surveillance Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Accelerate Diagnostics, Inc.
  • 17.6. Alifax S.r.l.
  • 17.7. Becton, Dickinson and Company
  • 17.8. bioMerieux SA
  • 17.9. BioSpace, Inc.
  • 17.10. Bio-Rad Laboratories, Inc.
  • 17.11. F. Hoffmann-La Roche Ltd
  • 17.12. Illumina, Inc.
  • 17.13. Liofilchem S.r.l.
  • 17.14. Lumed, Inc.
  • 17.15. Luminex Corporation
  • 17.16. Merck & Co., Inc.
  • 17.17. Oxford Nanopore Technologies plc
  • 17.18. Pfizer Inc.
  • 17.19. QIAGEN N.V.
  • 17.20. Seegene, Inc.
  • 17.21. Siemens Healthineers AG
  • 17.22. SyntBioLab, Inc.
  • 17.23. T2 Biosystems, Inc.
  • 17.24. Thermo Fisher Scientific, Inc.
  • 17.25. Wolters Kluwer N.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 128. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 129. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. G7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. G7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 146. G7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 147. G7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. G7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. G7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. NATO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. NATO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 152. NATO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 153. NATO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. NATO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. NATO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)